Natixis Atara Biotherapeutics, Inc. Transaction History

Natixis

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$4.69 - $9.84 $880,782 - $1.85 Million	-187,800 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$8.44 - $16.89 $4.85 Million - $9.71 Million	-574,900 Reduced 75.38%	187,800 $1.75 Million
Q4 2021 Feb 14, 2022	BUY	$14.7 - $19.89 $9.33 Million - $12.6 Million	635,000 Added 497.26%	762,700 $12 Million
Q3 2021 Nov 12, 2021	BUY	$11.99 - $17.9 $1.53 Million - $2.29 Million	127,700 New	127,700 $2.29 Million

85M

18.4K

51.3K

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $728M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.